Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Stock Code: 01399) (the "Company")

ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2)(h) OF THE LISTING RULES

This announcement is made by Veson Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rules 13.51B(2) and 13.51(2)(h) of The Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the regulatory announcement dated 4 December 2023 published by the Stock Exchange (the "**Regulatory Announcement**") in relation to, among others, the public censure of Dr. Loke Yu ("**Dr. Loke**"), a non-executive director of the Company. Dr. Loke is an independent non-executive director, the chairman of the audit committee, a member of the remuneration committee and a member of the nomination committee of the board of directors of Hong Kong Resources Holdings Limited (stock code: 2882) ("**HKRH**"). Dr. Loke was publicly censured by the Listing Committee of the Stock Exchange (the "Listing Committee") for breaching Rule 3.08 of the Listing Rules and his declaration and undertaking given to the Stock Exchange in the form set out in Appendix 5B to the Listing Rules during his tenure of directorship in HKRH in connection with the failure to maintain together with other directors of HKRH adequate and effective internal controls for HKRH's money lending business (the "**Disciplinary Action**"). Dr. Loke has been directed by the Listing Committee to attend 20 hours of training on regulatory and legal topics including Listing Rules compliance (the "**Training Requirement**").

For the avoidance of doubt, the Regulatory Announcement relates to HKRH only and (save for the above regarding Dr. Loke) does not involve any director or senior management of the Company.

The board (the "**Board**") of directors (the "**Directors**") of the Company (other than Dr. Loke) has reviewed the Regulatory Announcement (and the statement of disciplinary action referred therein). The Board (other than Dr. Loke) considers that Dr. Loke remains suitable to act as a non-executive Director for the following reasons:

- 1. No findings and conclusions set out in the Regulatory Announcement stated that Dr. Loke is unsuitable to act as a director of Hong Kong listed companies;
- 2. The incidents detailed in the Regulatory Announcement do not involve any dishonesty, fraud or integrity issues on the part of Dr. Loke; and
- 3. Dr. Loke has confirmed that he will attend 20 hours of training on regulatory and legal topics including Listing Rules compliance.

Save as disclosed in this announcement, Dr. Loke has confirmed to the Company that there is no other information relating to him that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company. Given that Dr. Loke has confirmed to the Company that he will be complying with the Training Requirement, the Board does not believe that Dr. Loke's ability to continue as a non-executive Director will be adversely affected.

By order of the Board Veson Holdings Limited Feng Ming Zhu Chairman

Hong Kong, 5 December 2023

As at the date of this announcement, the Board comprises Mr. Feng Ming Zhu, Ms. Lian Xiu Qin and Mr. Ni Chen Hui being the executive Directors, Dr. Loke Yu being the non-executive Director, and Mr. Heng Ja Wei Victor, Mr. Lam Yau Yiu and Mr. Cheung Wai Kwok Gary being the independent non-executive Directors.